NASDAQ:TYME

Tyme Technologies (TYME) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.29
$0.32
50-Day Range
$0.24
$0.35
52-Week Range
$0.22
$1.14
Volume
2.68 million shs
Average Volume
1.01 million shs
Market Capitalization
$53.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TYME stock logo

About Tyme Technologies Stock (NASDAQ:TYME)

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

TYME Stock News Headlines

Elon’s New A.I. Device is About to Shock the World
Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”
How to Get More From Your Air Fryer
Elon’s New A.I. Device is About to Shock the World
Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”
Ninja Foodi Beef Stew
Eden Green Launches Flagship Herb Program
Clos Apalta: fabulous wines from Chile
The 8 Best New Colognes of 2024 (So Far)
Women's Health
See More Headlines
Receive TYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
4/30/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TYME
Fax
N/A
Employees
17
Year Founded
N/A

Profitability

Net Income
$-23,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.47 per share

Miscellaneous

Free Float
143,104,000
Market Cap
$53.50 million
Optionable
Optionable
Beta
0.93
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives


TYME Stock Analysis - Frequently Asked Questions

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.03.

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

This page (NASDAQ:TYME) was last updated on 4/30/2024 by MarketBeat.com Staff

From Our Partners